Programme Parameters
Advanced Postgrad
3 Days (4.5 Hrs)
Online (e-LMS)
• Prior working knowledge of the field and comfort with core tools and quantitative reasoning.
• A laptop or desktop with a stable internet connection.
• Willingness to complete assignments and the capstone project.
About This Course
Advanced Course on CAR-T Therapy: Oncology and Beyond takes a deep look at one of the most powerful living drugs. You learn how chimeric antigen receptor T cells are engineered and manufactured, how they work against blood and solid tumours, and how their toxicities (like cytokine release) are managed. The course then explores the frontier — next-generation designs and applications beyond cancer, from autoimmunity to infection. You finish able to reason in depth about CAR-T therapy and its trajectory. A verified e-Certificate of competency and e-Marksheet from the Deep Science & Technology Consortium.
🎯 Program Aim
This advanced course covers CAR-T cell therapy — its design, manufacture and clinical use in cancer, plus emerging applications beyond oncology.
📋 Course Objectives
1. Explain CAR-T design and manufacture.
2. Understand CAR-T mechanism against tumours.
3. Manage CAR-T toxicities and resistance.
4. Explore next-generation CAR designs.
5. Survey applications beyond oncology.
👥 Who Should Enroll?
• Oncology and immunology researchers
• Cell-therapy and biotech professionals
• Clinical and pharma R&D staff
• Students of immunotherapy
🚀 Key Learning Outcomes
• An advanced understanding of CAR-T therapy.
• A mechanism-to-frontier perspective.
• A foundation in cell therapy.
• A verified e-Certificate of competency and e-Marksheet from the Deep Science & Technology Consortium.
💎 What You'll Gain
Live & Recorded Sessions
Lifetime access to class recordingse-Certificate on Completion
Cryptographically verified credentialPost-Programme Support
Direct access to mentors & councilHands-On Experience
Notebooks, real-world code & datasetsCurriculum Outline
CAR-T in Haematological Malignancy
• Approved indications and the pivotal trial evidence behind each
• Patient selection, bridging therapy and lymphodepletion regimens
• Response assessment and durability in lymphoma, leukaemia and myeloma
Why Patients Relapse
• Antigen loss and lineage switch as escape mechanisms
• T-cell exhaustion and failure of persistence
• Tumour microenvironment suppression of infused cells
The Harder Problem
• Trafficking, infiltration and physical barriers in solid tumours
• Antigen heterogeneity and on-target off-tumour toxicity risk
• Armoured CARs, cytokine support and combination strategies
Non-Malignant Applications
• CAR-T in autoimmune disease and the emerging clinical evidence
• CAR-Treg and CAR-NK approaches, and how they differ in risk profile
• Fibrosis, infection and senescence as investigational targets
Delivery and Access
• Toxicity management protocols and centre accreditation requirements
• Point-of-care manufacturing and decentralised models
• Cost, reimbursement and access in cost-constrained health systems
Technical Specifications
| Parameter | Requirement |
|---|---|
| Covered Tool / Platform | Python |
| Covered Tool / Platform | Jupyter Notebook |
| Covered Tool / Platform | Google Colab |
| Covered Tool / Platform | Microsoft Excel |
| Covered Tool / Platform | Relevant Online Databases |
Frequently Asked Questions
Scholar Feedback & Reviews
Based on 0 scholar submissions
Rating Breakdown
No verified reviews published yet. Be the first to share your academic experience.
Leave Scholar Feedback
Your rating will help prospective scholars. Ratings below 3 stars are routed privately to the faculty mentor for immediate response.
